Gordie Nye News

Atlantic Therapeutics appoints Gordie Nye as Chairman

Seroba’s investee company, Atlantic Therapeutics, which is focused on treating conditions of the pelvic floor and surrounding tissues, has appointed Gordie Nye as its Chairman.

After working with Gillette and Reebok, Gordie Nye forged his career as a CEO and Director of venture and private equity-backed medical device start-ups and buyouts. Of particular note are A-Company Orthodontics, Critikon and ZELTIQ Aesthetics, all of which saw excellent returns for investors. Nye is currently CEO of R2 Dermatology, a start-up that is set to commercialise a Harvard University technology – familiar territory for Nye who did the same at ZELTIQ, the maker of CoolSculpting, arguably the most valuable device company in the Aesthetics industry.

Atlantic Therapeutics CEO, Steve Atkinson, previously teamed up with Nye at ZELTIQ and Critikon. Atkinson says: “I am delighted Gordie has joined Atlantic Therapeutics as Chairman.  His involvement is an endorsement of the huge potential for INNOVO® and Gordie’s expertise in marketing medical devices to consumers will be invaluable to management as we strive to build value for our company and investors.”

Nye says “Typically resulting in incontinence and/or poor sexual health, a weak pelvic floor adversely affects the dignity, social life, and relationships of millions of people. Few conditions are so widespread yet so poorly served by the healthcare industry.  Surgery is a last resort, and conservative treatments in this category typically involve internally inserted devices that can be embarrassing and are unpleasant to use.  INNOVO® is safe, effective, wearable, and is an embarrassment-free device to restore pelvic floor strength.  As Chairman of Atlantic Therapeutics, I look forward to working with Steve and his team to achieve widespread adoption of INNOVO®.”

Ends.

For further information: Please contact Vicky La Touche-Price, Seroba Life Sciences on +353 1 6334028 or visit RestoreTheFloor.

Recent Articles

Endotronix News

FDA Approval for Endotronix Pivotal Trial

Dublin, Ireland and LISLE, IL, USA – AUGUST 1, 2019 – Seroba’s portfolio company, Endotronix, Inc., a digital health and […]

Read More
Quanta News

Quanta Raises $48 million in Series C Funding Round

Alcester, Warwickshire, UK, 29 July 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical […]

Read More
Endotronix News

Endotronix Enrolls 1st Patient in SIRONA II CE Mark Trial

LISLE, IL – JULY 15, 2019 – Endotronix, Inc., a digital health and medical technology company dedicated to advancing the […]

Read More
Home V2

Seroba Invests in Storm Therapeutics

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top